User:Mr. Ibrahem/Memantine

From Wikipedia, the free encyclopedia

Mr. Ibrahem/Memantine
Clinical data
Trade namesAxura, Ebixa, Namenda, others[1]
AHFS/Drugs.comMonograph
MedlinePlusa604006
License data
Pregnancy
category
  • AU: B2
Routes of
administration		By mouth
Drug classNMDA receptor inhibitor[2]
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Bioavailability~100%
MetabolismLiver (<10%)
Elimination half-life60–100 hours
ExcretionKidney
Identifiers
  • 3,5-dimethyltricyclo[3.3.1.13,7]decan-1amine
    or
    3,5-dimethyladamantan-1-amine
Chemical and physical data
FormulaC12H21N
Molar mass179.307 g·mol−1
3D model (JSmol)
  • NC12CC3(CC(C1)(CC(C2)C3)C)C
  • InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3 checkY
  • Key:BUGYDGFZZOZRHP-UHFFFAOYSA-N checkY
  (verify)

Memantine is a medication used to treat moderate-to-severe Alzheimer's disease.[2][3] It is less preferred than acetylcholinesterase inhibitors such as donepezil.[3] Treatment should only be continued if beneficial effects are seen.[3] It is taken by mouth.[2]

Common side effects include headache, constipation, sleepiness, and dizziness.[2][3] Severe side effects may include blood clots, psychosis, and heart failure.[3] It is believed to work by blocking NMDA receptors.[2]

Memantine was approved for medical use in the United States in 2003.[2] It is available as a generic medication.[3] A month supply in the United Kingdom costs the NHS about 1.60 GBP as of 2019.[3] In the United States the wholesale cost of this amount is about US$5.50.[5] In 2017, it was the 149th most commonly prescribed medication in the United States, with more than four million prescriptions.[6][7]

References[edit]

  1. ^ "International brands for memantine". Drugs.com. Retrieved 7 August 2017.
  2. ^ a b c d e f g h "Memantine Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
  3. ^ a b c d e f g h British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 303–304. ISBN 9780857113382.
  4. ^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 7 September 2020.
  5. ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
  6. ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
  7. ^ "Memantine Hydrochloride - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Memantine&oldid=1221525379"